Ionis' antisense-based drug platform and broad pipeline support a positive moat trend.
We are increasing our fair value for Alnylam to $111 per share from $92 following third-quarter earnings, primarily to reflect our updated pricing and market share expectations for the company’s amyloidosis candidate patisiran. We believe patisiran’s safety and efficacy profile places it head and shoulders above competitor Ionis’ drug inotersen, despite inotersen’s more convenient subcutaneous dosing. In addition, we adjusted our model to incorporate the pipeline progression of lumasiran (former...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.